Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia

Rituximab is an effective treatment for autoimmune cytopenias associated with chronic lymphocytic leukemia. Despite the incorporation of rituximab into fludarabine-based chemotherapy regimens, the incidence of autoimmune cytopenias has remained high. Inadequate rituximab exposure due to rapid antibo...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Mo, Clifton C., Njuguna, Ndegwa, Beum, Paul V., Lindorfer, Margaret A., Vire, Berengere, Lee, Elinor, Marti, Gerald, Wilson, Wyndham H, Taylor, Ronald P., Wiestner, Adrian
Format: Artigo
Idioma:Inglês
Publicat: Ferrata Storti Foundation 2013
Matèries:
Original Articles and Brief Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3729907/
https://ncbi.nlm.nih.gov/pubmed/23716541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2012.080929
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars